research Baricitinib Results in Eyebrow and Eyelash Growth in Patients With Alopecia Areata Who Do Not Achieve 20% or Less Scalp Hair Loss
Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
Search
for
Sort by
Research
120-150 / 1000+ results 
research Efficacy of Systemic Minoxidil and Tofacitinib Combination in Treatment-Resistant Alopecia Universalis
Using minoxidil and tofacitinib together can effectively treat severe hair loss.
research Adjuvant Treatment with Oral Minoxidil for Refractory Alopecia Areata to JAK Inhibitors
Combining oral minoxidil with JAK inhibitors helps regrow hair in severe alopecia areata cases.
research Systemic Tofacitinib Treatment in Pediatric Patients with Resistant Alopecia Areata
Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
research Growth Factors and Microneedling in Alopecia Areata: A Narrative Review
Using growth factors and microneedling shows promise for hair regrowth in Alopecia Areata, but more research is needed.
research Combination of Baricitinib and Conventional Immunomodulating Therapy for Alopecia Totalis
Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.
research Rethinking Alopecia Scores: Correlating Measures of Hair Loss with Established Photographic Scoring Systems
The conclusion suggests that a new system for measuring hair loss could be created using automated analysis of photographs.
research Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
research Current Diagnostic and Therapeutic Practices in Alopecia Areata in Two Mediterranean Countries: A Survey-Based Study
There are significant gaps and inconsistencies in diagnosing and treating alopecia areata in Greece and Italy.
research Combination Therapy With CGF and Microneedling-Assisted Compound Betamethasone for Resistant Alopecia Areata: A Pilot Study
Combining CGF and microneedling with betamethasone effectively treats resistant alopecia areata.
research Patient-Reported Outcomes for Scalp, Eyebrow, and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from Two Phase 3 Clinical Trials
Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
research Topical Calcipotriol Therapy for Mild-to-Moderate Alopecia Areata: A Retrospective Study
Calcipotriol cream can effectively and safely treat mild-to-moderate patchy hair loss.
research Trichoscopic Patterns of Nonscarring Alopecia
Different patterns on the scalp help diagnose types of hair loss without needing a biopsy.
research Among Scalp Non-Responder Patients with Eyebrow/Eyelash Regrowth in the First Year, Continued Treatment with Baricitinib Resulted in Meaningful Scalp Responses for Patients with Severe Alopecia Areata
Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.
research Hair Regrowth in Alopecia Areata Patients: Insights from a Case Study Using Mesenchymal Stem Cell Conditioned Media
Mesenchymal Stem Cell Conditioned Media can significantly regrow hair in alopecia areata patients.
research Superficial Cryotherapy Versus Intralesional Corticosteroid Injection in Alopecia Areata: A Comparative Clinical and Dermoscopic Study
Cryotherapy and steroid injections are similarly effective and safe for treating alopecia areata.
research Oral Baricitinib Restores Hair Loss in Alopecia Areata
Baricitinib, a medication taken by mouth, was effective in regrowing hair for people with severe hair loss.
research Evaluation and Diagnosis of the Hair Loss Patient
Trichoscopy is a quick, cost-effective tool for diagnosing different hair loss conditions.
research Baricitinib Maintains Regrowth of Hair, Eyebrows, and Eyelashes Over 3 Years
Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.
research Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers
Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
research Bimatoprost
Bimatoprost may help treat hair loss from alopecia areata.
research Response to 'Vitamin D Status in Scarring and Nonscarring Alopecia'
The document suggests using a topical Vitamin D treatment for hair loss rather than oral supplements and calls for more research.
research This Month in JAAD: October 2021
Oral baricitinib is effective and safe for treating alopecia areata.
research In Reply
Combining pulsed prednisone with tofacitinib can lead to lasting hair regrowth in severe alopecia areata patients.
research Autophagy Stimulation Improves Erythroid Proliferative Capacity in Models of SF3B1 Mutant MDS
Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
research The Experts Meetings on Psoriasis: Recommendations for Daily Practice
Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
research Scoring Systems for Pemphigus
The Pemphigus Disease Area Index and Autoimmune Bullous Skin Disorder Intensity Score are the best tools for assessing pemphigus severity.
research Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis: A Randomized, Double-Blind, Placebo-Controlled Trial
Botulinum toxin type A did not help regrow hair in severe alopecia cases.
research Clinical Severity Does Not Reliably Predict Quality of Life in Women With Alopecia Areata, Telogen Effluvium, or Androgenic Alopecia
How bad a woman's hair loss is doesn't always match how it affects her happiness and daily life.
research Physician and Patient-Reported Severity and Quality of Life Impact of Alopecia Areata: Results from a Real-World Survey in Five European Countries
Alopecia areata severely impacts quality of life, causing anxiety, depression, and work impairment.